​

Tarsus Pharmaceuticals (TARS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TARS Stock Forecast

Tarsus Pharmaceuticals (TARS) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $98.00, with a high of $105.00 and a low of $89.00. This represents a 18.40% increase from the last price of $82.77.

$20 $37 $54 $71 $88 $105 High: $105 Avg: $98 Low: $89 Last Closed Price: $82.77

TARS Stock Rating

Tarsus Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 8 Buy (80.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 8 1 Strong Sell Sell Hold Buy Strong Buy

TARS Price Target Upside V Benchmarks

TypeNameUpside
StockTarsus Pharmaceuticals18.40%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts249
Avg Price Target$102.50$98.00$88.78
Last Closing Price$82.77$82.77$82.77
Upside/Downside23.84%18.40%7.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-7---7
Aug, 2618---9
Jul, 2618---9
Jun, 2618---9
May, 2618---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2026Jefferies$105.00$89.6717.10%26.86%
Aug 12, 2026Mazahir AlimohamedOppenheimer$100.00$69.4643.97%20.82%
Aug 03, 2026Mizuho Securities$98.00$59.0465.99%18.40%
Jul 21, 2026Eddie HickmanGuggenheim$89.00$56.2558.22%7.53%
Feb 05, 2026Goldman Sachs$68.00$64.595.28%-17.84%
Dec 08, 2025Barclays$100.00$82.2321.61%20.82%
Nov 20, 2025Mizuho Securities$100.00$77.1129.68%20.82%
Nov 06, 2025Andrea TanGoldman Sachs$51.00$67.25-24.16%-38.38%
Oct 20, 2025H.C. Wainwright$88.00$72.9320.66%6.32%
May 02, 2025Eddie HickmanGuggenheim$84.00$47.3677.36%1.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2026JefferiesBuyBuyhold
Aug 12, 2026OppenheimerOutperformOutperformhold
Jul 21, 2026GuggenheimBuyBuyhold
Feb 05, 2026Goldman SachsNeutralNeutralhold
Dec 08, 2025BarclaysOverweightOverweightinitialise
Nov 06, 2025Goldman SachsNeutralNeutralhold
Oct 20, 2025H.C. WainwrightNeutralNeutralhold
Oct 20, 2025H.C. WainwrightBuyBuyhold
May 02, 2025GuggenheimBuyBuyhold
Mar 06, 2025JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.67$-2.52$-4.62$-3.07$-1.59---
Avg Forecast$-0.57$-2.36$-4.79$-3.22$-1.69$1.91$4.78$7.06
High Forecast$-0.48$-2.08$-4.46$-2.94$-0.31$3.02$5.57$7.76
Low Forecast$-0.66$-2.60$-5.22$-3.47$-2.64$0.50$3.99$6.37
Surprise %17.54%6.78%-3.55%-4.66%-5.92%---

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.03M$25.82M$17.45M$182.95M$451.36M---
Avg Forecast$49.07M$25.86M$9.70M$175.34M$317.67M$513.16M$708.62M$832.14M
High Forecast$54.62M$27.87M$12.17M$181.03M$335.41M$518.42M$763.13M$896.15M
Low Forecast$43.25M$23.48M$7.15M$171.31M$295.08M$507.89M$655.85M$770.17M
Surprise %16.22%-0.16%79.83%4.34%42.08%---

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.83M$-62.09M$-135.89M$-115.55M$-66.42M---
Avg Forecast$-16.83M$-69.44M$-135.89M$-94.26M$-63.17M$51.65M$140.45M$207.30M
High Forecast$-14.24M$-61.14M$-130.95M$-86.50M$-9.09M$88.73M$163.63M$228.03M
Low Forecast$-19.30M$-76.46M$-153.50M$-102.01M$-77.64M$14.57M$117.28M$187.23M
Surprise %-17.82%-10.59%-22.60%5.15%---

TARS Forecast FAQ

Is Tarsus Pharmaceuticals stock a buy?

Tarsus Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tarsus Pharmaceuticals is a favorable investment for most analysts.

What is Tarsus Pharmaceuticals's price target?

Tarsus Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $98 over the next 12 months. The price target range spans from $89 at the low end to $105 at the high end, suggesting a potential 18.40% change from the previous closing price of $82.77.

How does Tarsus Pharmaceuticals stock forecast compare to its benchmarks?

Tarsus Pharmaceuticals's stock forecast shows a 18.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tarsus Pharmaceuticals over the past three months?

  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tarsus Pharmaceuticals’s EPS forecast?

Tarsus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $1.91, marking a -220.13% decrease from the reported $-1.59 in 2025. Estimates for the following years are $4.78 in 2027, and $7.06 in 2028.

What is Tarsus Pharmaceuticals’s revenue forecast?

Tarsus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $513.16M, reflecting a 13.69% increase from the reported $451.36M in 2025. The forecast for 2027 is $708.62M, and $832.14M for 2028.

What is Tarsus Pharmaceuticals’s net income forecast?

Tarsus Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $51.65M, representing a -177.77% decrease from the reported $-66.418M in 2025. Projections indicate $140.45M in 2027, and $207.3M in 2028.